Germany’s Merck Realigns Drug R&D Strategy
In a move to advance productivity, the healthcare division of Germany’s Merck is realigning its drug discovery and launch strategy. Global healthcare research chief Danny Bar-Zohar told a conference call this week that the Darmstadt-based company will seek to strike a new balance between in-house R&D and external collaboration.
